All In Biotech

Drug Trial Radar · NCT05988034

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

A Multiple-dose, Randomized, Double-blind, Placebo-controlled, Active-Comparator, Parallel Study to Investigate the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Nov 8, 2019

Primary completion

Jan 22, 2020

Study completion Mar 31, 2020

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effects of therapeutic and supratherapeutic doses of avacopan on the heart rate corrected QT interval, using Fridericia's formula (QTcF).

Conditions

  • Electrocardiography

Interventions

  • AvacopanDrug

    Administered orally.

  • MoxifloxacinDrug

    Administered orally.

  • Placebo for avacopanDrug

    Administered orally.

  • Placebo for moxifloxacinDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in QTcFTime frame: Day -1 (baseline) and up to Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.